Skip to main content
Back

EVS-EN ISO 10993-17:2023+A1:2025

Biological evaluation of medical devices - Part 17: Toxicological risk assessment of medical device constituents (ISO 10993-17:2023 + ISO 10993-17:2023/Amd 1:2025)

General information

Valid from 15.01.2026
Base Documents
EN ISO 10993-17:2023; ISO 10993-17:2023; EN ISO 10993-17:2023/A1:2025; ISO 10993-17:2023/Amd 1:2025
Directives or regulations
None

Standard history

Status
Date
Type
Name
15.01.2026
Main + amendment
31.12.2025
Amendment
01.12.2023
Main
This document specifies the process and requirements for the toxicological risk assessment of medical device constituents. The methods and criteria used to assess whether exposure to a constituent is without appreciable harm are also specified. The toxicological risk assessment can be part of the biological evaluation of the final product, as described in ISO 10993-1.
The process described in this document applies to chemical characterization information obtained in line with ISO 10993-18. When a toxicological risk assessment of either the compositional information or analytical chemistry data (e.g. extractable data or leachable data) are required to determine whether the toxicological risks related to the constituents are negligible or tolerable.
The process described in this document is not intended to apply to circumstances where the toxicological risk has been estimated by other means, such as:
—  constituents, excluding cohort of concern or excluded chemicals, that are present in or extracted from a medical device at an amount representative of patient exposure below a relevant, toxicologically-based reporting threshold (see applicable requirements in ISO 10993-18:2020, Annex E and ISO/TS 21726);
—  a new or changed medical device for which chemical or biological equivalence has been established with an existing biocompatible or clinically established medical device (see applicable requirements in ISO 10993-18:2020, Annex C).
The process described in this document is also not applicable to:
—  medical device constituents that do not contact the body (e.g. in vitro diagnostics);
—  biological risks associated with physical interactions of the medical device with the body (i.e. application of mechanical forces, energy or surface morphology, etc.), provided that the chemical exposure is not changed;
—  active pharmaceutical ingredients of device-drug combination products or biologic components of device-biologic combination products as additional regulatory considerations can apply;
—  exposure to a particular constituent that arises from sources other than the device, such as food, water or air.

Required fields are indicated with *

*
*
*
PDF
39.68 € incl tax
Paper
39.68 € incl tax
Browse standard from 2.48 € incl tax
Standard monitoring

Customers who bought this item also bought

Main

EVS-EN ISO 10993-1:2026

Biological evaluation of medical devices - Part 1: Requirements and general principles for the evaluation of biological safety within a risk management process (ISO 10993-1:2025)
Newest version Valid from 15.01.2026
Main + amendment

EVS-EN ISO 10993-5:2009+A11:2025

Biological evaluation of medical devices - Part 5: Tests for in vitro cytotoxicity (ISO 10993-5:2009)
Newest version Valid from 02.06.2025
Main + amendment

EVS-EN ISO 10993-12:2021+A1:2025

Biological evaluation of medical devices - Part 12: Sample preparation and reference materials (ISO 10993-12:2021 + ISO 10993 12:2021/Amd 1:2025)
Newest version Valid from 01.10.2025
Main + amendment

EVS-EN ISO 10993-18:2020+A1:2023

Biological evaluation of medical devices - Part 18: Chemical characterization of medical device materials within a risk management process (ISO 10993-18:2020 + ISO 10993-18:2020/Amd 1:2022)
Newest version Valid from 15.08.2023